Oliveira-Maia AJ

Champalimaud Clinical Centre, Champalimaud Foundation, Lisbon, Portugal.

8 papers · ORCID

ArticlePsilocybin

A national approach in a European context: Multidisciplinary and multiprofessional recommendations on the clinical use of psychedelic substances.

Seybert C, Pires AM, Madeira L +5

Europe PMC2026
ArticleKetamine

Erratum to "Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study" [European Neuropsychopharmacology 107 (2026) 112801].

Reif A, Anıl YA, Bitter I +11

Europe PMC2026
ArticleKetamine

Trajectory of response to esketamine nasal spray for treatment resistant depression: Findings from ESCAPE-TRD.

Young AH, Bartova L, Cardoner N +9

Europe PMC2026
ArticleKetamine

Response to: Commentary on "Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study".

Reif A, Anıl Yağcıoğlu AE, Bitter I +11

Europe PMC2026
ArticleKetamine

Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study.

Reif A, Anıl YA, Bitter I +11

Europe PMC2026
ArticlePsilocybin

Concomitant use of antidepressants and classic psychedelics: A scoping review.

Tap SC, Thomas K, Páleníček T +4

Europe PMC2025
ArticlePsilocybin

Quality of reporting on psychological interventions in psychedelic treatments: a systematic review.

Seybert C, Schimmers N, Silva L +6

Europe PMC2025
ArticleKetamine

Safety and tolerability of esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression.

McIntyre RS, Bitter I, Buyze J +9

Europe PMC2024